Demonstrating Pemetrexed induced Thymidylate Synthase inhibition in non-small cell lung cancer in vivo: a pilot study.

Demonstrating Pemetrexed induced Thymidylate Synthase inhibition in non-small cell lung cancer in vivo: a pilot study. - Alimta study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON32208

Enrollment

Registered

2008-07-23

Start date

2008-09-26

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NSCLC

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patient age 18 years or older Histological diagnosis of NSCLC Scheduled for treatment with pemetrexed Tumour diameter min. 3cm (to minimize partial volume effects) within the chest Able to remain supine for 60 minutes Written informed consent

Exclusion criteria

Exclusion criteria: Pregnant or lactating patients Claustrophobia Patients having metal implants (e.g. pacemakers)

Design outcomes

Primary

Measure	Time frame
Change of 18F-FLT uptake as measured with time lapse of 4 hrs after pemetrexed. 18F-FLT changes versus clinical response measured with RECIST.	—

Countries

Netherlands

Outcome results